NCT03214497 is a NA clinical trial of Protector in Anesthesia, sponsored by Schulthess Klinik.

Who is sponsoring NCT03214497?

NCT03214497 is sponsored by Schulthess Klinik.

What drugs are being tested in NCT03214497?

Interventions in NCT03214497: Protector, Supreme.

What condition does NCT03214497 study?

NCT03214497 studies Anesthesia.

Is NCT03214497 still recruiting?

NCT03214497 is currently completed. Last updated 2 December 2017.

Last reviewed 2017-12-02 · How we verify

NCT03214497

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Protector™ Versus Supreme® Laryngeal Mask Airway

Completed NA Last updated 2 December 2017

What this trial tests

NA trial testing Protector in Anesthesia in 96 participants. Completed in 28 November 2017.

Timeline

12 July 2017

Primary endpoint
28 November 2017

28 November 2017

Quick facts

Lead sponsor	Schulthess Klinik
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	treatment
Enrollment	96
Start date	12 July 2017
Primary completion	28 November 2017
Estimated completion	28 November 2017
Sites	1 location across Switzerland

Drugs / interventions tested

Protector
Supreme

Conditions studied

Anesthesia — all drugs for Anesthesia →

Sponsor

Schulthess Klinik

Who can join

Adults 18 to 75, any sex, with Anesthesia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The goal of this study is to compare the oropharyngeal leak pressure of the Protector Laryngeal mask with the Supreme laryngeal mask. Other secondary parameters will be studied.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Anesthesia

Currently open trials in the same condition.

NCT07294092 — Ketamine and Propofol NeuroImaging · EARLY_PHASE1 · recruiting
NCT07290205 — Remimazolam NeuroImaging · EARLY_PHASE1 · recruiting
NCT07465185 — Intrathecal Bupivacaine With or Without Dexmetomidine for Cesserian Delivery · Phase 2 · recruiting
NCT07269808 — Sedation During Endoscopy Using Remimazolam: Efficacy in a Novel Exploration · Phase 3 · recruiting
NCT07443254 — Prospective IR-led Sedation Feasibility · Phase 1, PHASE2 · recruiting

Other Schulthess Klinik trials

Trials by the same sponsor.

NCT07197593 — Validity and Reliability of Calf Raise Tests in Patients With Achilles Tendon Rupture and Lateral Ankle Sprain · NA · not yet recruiting
NCT06223737 — Spine Deformity Patients With Optoelectronic Motion Capture · NA · not yet recruiting
NCT06330129 — Validity and Reliability of Trunk Strength Device · NA · completed
NCT06612853 — Validation of the Single-item Sleep Quality Scale · recruiting
NCT06555991 — Translation and Validation of the SIRSI and TSK-SI Into German · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03214497 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Schulthess Klinik
Last refreshed: 2 December 2017

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03214497.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing